

# Hypoxia-Inducible Factor-1 $\alpha$ (HIF-1 $\alpha$ ) Gene Polymorphisms, Circulating Insulin-Like Growth Factor Binding Protein (IGFBP)-3 Levels and Prostate Cancer

Haojie Li,<sup>1\*</sup> Glenn J. Bubley,<sup>2</sup> Stephen P. Balk,<sup>2</sup> J. Michael Gaziano,<sup>3,4</sup> Michael Pollak,<sup>5</sup> Meir J. Stampfer,<sup>1,3,6</sup> and Jing Ma<sup>1</sup>

<sup>1</sup>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

<sup>2</sup>Department of Medicine, Beth Israel Deaconess Medical Center; Harvard Medical School, Boston, Massachusetts

<sup>3</sup>Division of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

<sup>4</sup>Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts

<sup>5</sup>Cancer Prevention Centre, McGill University, Montreal, Canada

<sup>6</sup>Departments of Epidemiology and Nutrition, Harvard School of Public Health, Boston, Massachusetts

**BACKGROUND.** The Hypoxia-inducible factor-1 (HIF-1) plays an important role in regulating angiogenesis in response to hypoxia. Two non-synonymous polymorphisms (*P582S C→T* and *A588T G→A*) in the coding region of the subunit 1 $\alpha$  (HIF-1 $\alpha$ ) gene have been associated with enhanced stability of the protein and androgen-independent prostate cancer (CaP). Insulin-like growth factor binding protein (IGFBP)-3 mRNA is more abundantly expressed in hypoxia-related inflammatory angiogenesis and recent *in vivo* data suggest that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis.

**METHODS.** We examined the association of these polymorphisms with CaP among 1,072 incident cases and 1,271 controls, and further explored their joint associations with various prediagnostic plasma vascular endothelial growth factor (VEGF), IGF-I, and IGFBP-3 levels.

**RESULTS.** Neither the *P582S* nor the *A588T* polymorphism was associated with risk of overall or metastatic/fatal CaP. However, we found that, among men with the homozygous CC wild-type (but not CT/TT) of the HIF-1 $\alpha$  *P582S*, higher IGFBP-3 levels ( $\geq$  vs. <median) were associated with a 28% (95% CI, 0.55–0.95;  $P_{\text{interaction}} = 0.01$ ) lower risk of overall CaP and a 53% (0.25–0.88;  $P_{\text{interaction}} = 0.11$ ) lower risk of metastatic and fatal CaP. The *A588T* polymorphism was too rare to assess interactions.

**CONCLUSIONS.** The two HIF-1 $\alpha$  gene polymorphisms were not directly associated with CaP, but the interaction between the *P582S* polymorphism and IGFBP-3 merits further evaluation in mechanistic studies.

**KEY WORDS:** insulin-like growth factor (IGF)-I; vascular endothelial growth factor (VEGF); prospective; nested case-control study

## INTRODUCTION

Hypoxia-inducible factor-1 (HIF-1), composed of an  $\alpha$  and a  $\beta$  subunit [1], is a pivotal regulator of cellular response to hypoxia [2]. The transcriptional activity of HIF-1 is determined by the oxygen-regulated expression of the HIF-1 $\alpha$  subunit [3], which is hydroxylated and degraded rapidly under normoxia through von Hippel–Lindau (VHL) mediated ubiquitination

Haojie Li and Glenn J. Bubley contributed equally to this work.

Grant sponsor: The National Institutes of Health; Grant numbers: CA-42182, CA-58684.

\*Correspondence to: Dr. Haojie Li, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Room 452, 181 Longwood Ave, Boston, MA 02115. E-mail: haojie.li@channing.harvard.edu

whereas it becomes stabilized or even induced in response to hypoxia [3]. HIF-1 $\alpha$  is overexpressed in many tumors [4,5] and a significant association between such overexpression and mortality has been reported for many cancer types [2]. In prostate cancer cell lines, expression of HIF-1 $\alpha$  protein is positively associated with cell growth rates and metastatic potential [6,7]. In humans, expression levels of HIF-1 $\alpha$  are upregulated in high-grade prostate intraepithelial neoplasia (PIN) lesions (vs. adjacent normal tissue) and are further enhanced in primary and metastatic prostate cancer [4,8,9].

Two germline single-nucleotide polymorphisms within the oxygen-dependent degradation (ODD)/pVHL binding domain (in exon 12) of the HIF-1 $\alpha$  gene were identified [10]. *P582S* causes a change from proline to serine at codon 582, and *A588T* causes a change from alanine to threonine at codon 588. Although the functionality of these polymorphisms are not completely clear, both the *P582S* [11–13] and *A588T* [11] variants (vs. wild-type) yielded significantly higher transcription activity. Interestingly, our group recently identified the *P582S* C $\rightarrow$ T as a somatic mutation in bone marrow metastatic biopsies from men with androgen-independent prostate cancers; and our in vitro experiment demonstrated that, under normoxic conditions, this mutation had significantly higher transcription activity, which reflected increased HIF-1 $\alpha$  protein expression [13]. Another group also found the same somatic mutation in prostate tumors [14]. One clinical case-control study found that the *P582S* T-containing variant genotypes were more common among men with androgen-independent prostate cancer [15]. Taken together, these data suggest that the HIF-1 $\alpha$  polymorphisms might be related to risk of prostate cancer, especially the more aggressive form, and provide the rationale for the current investigation.

HIF-1 plays a major role in tumor progression and metastasis through activation of various genes that are linked to regulation of angiogenesis, cell survival, energy metabolism and apoptotic and proliferative responses [2,16]. Under hypoxic conditions, HIF-1 activates the vascular endothelial growth factor (VEGF) gene, leading to increased production of VEGF, a potent stimulator of angiogenesis [17,18]. Treatment of cultured cells with insulin, insulin-like growth factor-I (IGF-I), or IGF-2 induces HIF-1 $\alpha$  protein expression, which is in turn required for expression of IGF-2 [19–22]. These activities may promote cell proliferation and survival. For these reasons, HIF-1 has become an attractive target for the development of anti-cancer drugs [2,23]. IGFBP-3 mRNA is more abundantly expressed in hypoxia-related inflammatory angiogenesis [24,25], perhaps as part of a feedback mechanism. In vitro and in vivo studies suggest that IGFBP-3

attenuates prostate tumor growth [26] and has direct IGF-independent inhibitory effects on angiogenesis [27], thus may inhibit tumor progression.

Using a nested case-control design within the Physicians' Health Study, we investigated the associations of the HIF-1 $\alpha$  *P582S* and *A588T* polymorphisms with prostate cancer incidence and survival. We hypothesized that the HIF-1 $\alpha$  *P582S* (CC or CT) and *A588T* (GA) variant genotype may be associated with increased risk, especially with aggressive disease, and poorer survival after diagnosis. We and other previously showed that circulating levels of IGF-I are positively (whereas levels of IGFBP-3 are mostly inversely) associated with risk of prostate cancer [28–30], especially advanced-stage disease [28,29], therefore we further explored the relationship between these HIF-1 $\alpha$  polymorphisms and prediagnostic plasma levels of IGF-I, IGFBP-3, and VEGF in relation to prostate cancer incidence and aggressiveness.

## MATERIALS AND METHODS

### Study Population

The Physicians' Health Study (PHS) was a randomized, double-blind, placebo-controlled trial of aspirin and  $\beta$ -carotene among 22,071 healthy U.S. male physicians, aged 40–84 years, that began in 1982 [31]. During 1982 and 1984, 14,916 (68%) provided baseline blood samples prior to randomization [32], and more than 70% of the specimens were received between September and November in 1982. Through mailed baseline and follow-up questionnaires, we collected information on diet, lifestyle behaviors and medical history. Follow-up of the participants for morbidity and mortality is 97% complete to March 2005. Since 2003, information regarding disease progression and metastases was obtained from men with prostate cancer cases via additional follow-up questionnaires. Thus far, 87% of the eligible participants have responded, and less than 2% of participants have refused to participate or cannot because of cognitive problems.

Prostate cancer cases for the current study were drawn from participants who provided blood specimens at baseline and reported a diagnosis of prostate cancer between 1982 and 2000. Study investigators, unaware of the questionnaire or assay data, verified the reports of prostate cancer by participants and reviewed medical records and pathological reports to determine the tumor Gleason score, grade, and stage, according to the modified Whitmore-Jewett classification scheme [33]. The corresponding TNM staging to the Whitmore-Jewett system is as: stage A (T1N0M0), B (T2N0M0), C (T3N0M0), and D (TxN0M1, TxN1M0 or TxN1M1). We defined advanced-stage cancer as stage C and D diseases, and defined high-grade cancer as those with

Gleason score of 7 to 10 and those that were poorly differentiated. For each case, we selected one or two controls at random from those who had provided blood, were alive, had not had a prostatectomy, and had not reported a diagnosis of cancer (except for non-melanoma skin cancer) at the time the diagnosis was reported by the case subject. Controls were individually matched to cases by age ( $\pm 1$  year when feasible, else up to  $\pm 5$  years for older men) and smoking status (never, former, or current).

### Laboratory Assessment

**The HIF-1 $\alpha$  gene polymorphisms.** DNA was extracted from baseline blood specimens for these men. With the laboratory personnel blinded to the case-control status, all samples were genotyped using the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) at the Dana Farber/Harvard Cancer Center Genotyping Core. The HIF-1 $\alpha$ -RFLP (*P582S* and *A588T*) genotypes were determined by the PCR amplification, followed by restriction enzyme digestion, as described previously [10]. The lab personnel were unaware of case-control status. To assess genotyping reproducibility, they repeated a random 10% selection of the samples; all genotypes matched initial designated genotypes.

**Plasma concentrations of IGF-I, IGFBP-3, and VEGF.** Samples from cases and their matched controls were assayed in the same batch to minimize interassay variability, and aliquots from a pool of quality control plasma (10% of total sample) were inserted randomly. Laboratory personnel were unable to distinguish among case, control, and quality control samples. Plasma levels of IGF-I and IGFBP-3 were assayed by enzyme-linked immunosorbent assay with reagents from Diagnostic Systems Laboratory (Webster, TX) in the laboratory of M. N. Pollak at the Lady Davis Research Institute of the Jewish General Hospital and McGill University. The median intra-assay coefficients of variation (CV) for IGF-I, and IGFBP-3 from the blinded quality control samples were 4.5% and 4.0%, respectively. Plasma concentrations of VEGF for each man were assayed in duplicate using a microplate luminescence detection system (Dynex Technologies, Chantilly, VA) and a human VEGF immunoassay Quantiglo kit (R&D Systems, Minneapolis, MN). The median CV for the quality control samples was 22.8%. Additional details of the VEGF assay are described elsewhere [34].

### Statistical Analysis

We studied 1,072 men who developed prostate cancer during 18 years of follow-up and 1,271 controls.

Of these, 1,041 cases (and 1,234 controls) were assayed for the HIF-1 $\alpha$  *P582S* polymorphism and 1,066 cases (and 1,264 controls) for the HIF-1 $\alpha$  *A588T* polymorphism. Because the majority (94%) of men were Caucasians and analyses with and without the non-Caucasian men yielded similar results, we included men of all ethnic groups in this study to maximize the sample size.

We compared allele and genotype frequencies between cases and controls with the  $\chi^2$ -test. We examined the association of HIF-1 $\alpha$  gene polymorphisms with risk of developing prostate cancer, then refitted models for men who developed metastases or died from prostate cancer during the follow-up, and within subgroups based on disease aggressiveness (by stage and grade), age at diagnosis ( $< 65$  years or  $\geq 65$  years), or PSA-era (before or after 1990). Because very few men ( $< 2\%$ ) carried the HIF-1 $\alpha$  *P582S* *TT* genotype, we use the dominant model by combining men with the *CT* or the *TT* genotypes into a single group and compared them with the reference group (the wild-type) for all analyses. The results were similar from both conditional (matched) and unconditional (unmatched) logistic regression analyses, so we primarily report estimates (relative risks, RR and 95% confidence intervals, 95% CI) from unconditional logistic regression, adjusted for matching factors of age, smoking status, and duration of follow-up. The unconditional logistic regression model permits all control subjects to be included in each model for maximizing statistical power, which is especially important for the subgroup analyses. To assess the influence of these polymorphisms on prostate cancer-specific survival, with survival time calculated from date of diagnosis to date of death from prostate cancer or other causes, or the end of the follow-up in March 2005, hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models, adjusting for age at diagnosis and smoking status.

The joint associations of HIF-1 $\alpha$  polymorphisms with plasma levels (categorized by median) of IGF-I, IGFBP-3, and VEGF on prostate cancer were examined for the HIF-1 $\alpha$  *P582S* genotype only. The frequency of HIF-1 $\alpha$  *A588T* (*GA*) variant was too rare ( $< 2\%$ ) to examine interactions. Conditional logistic regression models were implemented. Included in these analyses were 661 cases and 661 matched controls for IGF-I and IGFBP-3 and 397 cases and 398 matched controls for VEGF. Because levels of IGF-I and IGFBP-3 were correlated ( $r = 0.46$ ,  $P < 0.0001$ ) and these two biomarkers have opposite effects on risk, it was necessary to adjust for them simultaneously. We further compared the age-, smoking status-, and batch-adjusted levels of IGF-I and IGFBP-3 and age- and smoking status-adjusted VEGF levels with the presence or absence of

the HIF-1 $\alpha$  *P582S* variant (*CT* or *TT*) genotype, using general linear regression models. All statistics were calculated using SAS (version 8.12; SAS Institute, Inc., Cary, NC) with a two-sided significance level of 0.05.

## RESULTS

On average, men were 69 years of age when prostate cancer was diagnosed. The median interval from baseline in 1982 to diagnosis was 11.0 years for these cancer patients, and the average follow-up duration after diagnosis was 9.2 years. Among control subjects, the genotype frequencies were 80.6% (*CC*), 17.9% (*CT*) and 1.5% (*TT*) for the *P582S* polymorphism and 98.7% (*GG*), 1.3% (*GA*) for the *A588T* polymorphism (no instances for the *A588T* *AA* variant genotype). The genotype distributions were in Hardy–Weinberg equilibrium. The genotype frequencies were similar to previous reports for Caucasian populations [10,15]; however, compared with a report in a Japanese population [11], the *A588T* polymorphism in these men was rare (1.3% in our controls vs. 8.2% in Japanese controls). Genotype frequencies for the HIF-1 $\alpha$  *P582S* and *A588T* polymorphisms did not differ significantly between cases and controls (Table I).

The *P582S* polymorphism was not associated with risk of overall prostate cancer (Table II, RR, 95% CI for *P582S* *CT* or *TT* vs. *CC* = 1.14, 0.93–1.40), regardless of age at diagnosis or calendar time (by PSA era), and was not related to prostate cancer-specific survival (HR, 95% CI for *P582S* *CT* or *TT* vs. *CC* = 0.90, 0.60–1.35). The HIF-1 $\alpha$  *P582S* polymorphism had no relationship with risk for advanced-stage, metastatic and fatal disease. We also found no association of the *A588T* polymorphism with prostate cancer risk and survival; however, this polymorphism was too rare in this population to draw meaningful conclusions.

Plasma levels of IGF-I, IGFBP-3, and VEGF measured from blood samples collected at the baseline, an average of 11 years before cancer diagnosis, were not significantly different between cases and controls or by the HIF-1 $\alpha$  *P582S* genotype (Table III). We found no interaction of the HIF-1 $\alpha$  *P582S* polymorphism with baseline levels of VEGF or IGF-I. Men with the *CT* or *TT* genotypes and higher plasma IGF-I levels tended to have higher risk of overall, advanced-stage, high-grade, metastatic, and fatal prostate cancer, but none of these were statistically significant. However, we found that, among men with the *CC* (but not *CT/TT*) wild-type of the HIF-1 $\alpha$  *P582S*, higher IGFBP-3 level

**TABLE I. Baseline Characteristics of Prostate Cancer Cases and Controls in the Physicians' Health Study**

	Cases (n = 1,072)	Controls (n = 1,271)
Age at baseline (year) <sup>a</sup>	58.9 $\pm$ 8.3	59.0 $\pm$ 8.1
Age at diagnosis (year)	69.4 $\pm$ 7.3	NA
Smoking status (%) <sup>a</sup>		
Current	9.5	8.9
Former	42.7	42.6
Disease aggressiveness, N (%)		
Stage AB	581 (54.2)	NA
CD	233 (21.7)	
Unknown	258 (24.1)	
Grade <sup>b</sup>		
Low	661 (61.7)	NA
High	384 (35.8)	
Unknown	27 (2.5)	
Metastatic/fatal prostate cancer <sup>c</sup>	184 (17.2)	NA
HIF-1 $\alpha$ gene polymorphism, N (%) <sup>d</sup>		
<i>P582S</i> <i>_CC</i>	818 (78.6)	995 (80.6)
<i>P582S</i> <i>_CT</i>	209 (20.1)	221 (17.9)
<i>P582S</i> <i>_TT</i>	14 (1.3)	18 (1.5)
<i>A588T</i> <i>_GG</i>	1,053 (98.8)	1,247 (98.7)
<i>A588T</i> <i>_GA</i>	13 (1.2)	17 (1.3)

<sup>a</sup>Matching variable.

<sup>b</sup>High-grade cancer included Gleason 7–10 or poorly differentiated tumors.

<sup>c</sup>Metastatic/fatal prostate cancer, cases died of prostate cancer and those who developed metastasis during the follow-up.

<sup>d</sup>Data availability: HIF-1 $\alpha$  *P582S* genotype, 1,041 cases and 1,234 controls; HIF-1 $\alpha$  *A588T* genotype, 1,066 cases and 1,264 controls.

**TABLE II. HIF-1 $\alpha$  P582S Gene Polymorphism and Risk of Prostate Cancer<sup>a</sup>**

	HIF-1 $\alpha$ P582S Polymorphism			
	CC		CT or TT	
	N	RR (Ref.)	N	RR (95% CI)
Number of controls		995		239
Overall prostate cancer	818	1.00	223	1.14 (0.93–1.40)
By tumor stage <sup>c</sup>				
Stage AB	436	1.00	129	1.23 (0.97–1.57)
Stage CD	178	1.00	49	1.14 (0.81–1.62)
By tumor grade <sup>b,c</sup>				
Low	506	1.00	133	1.10 (0.86–1.39)
High	288	1.00	88	1.28 (0.97–1.69)
Metastatic/fatal prostate cancer <sup>d</sup>	139	1.00	38	1.15 (0.77–1.70)
By age at diagnosis				
<65 years	227	1.00	65	1.10 (0.77–1.58)
$\geq$ 65 years	591	1.00	158	1.14 (0.90–1.44)
By PSA era				
Pre-PSA (1982–1990)	232	1.00	55	0.92 (0.63–1.34)
Post-PSA (1991–2000)	586	1.00	168	1.21 (0.96–1.53)

<sup>a</sup>Risk ratio (RR) and 95% confidence interval (95% CI); unconditional logistic regression, adjusting for age at study onset and smoking status at baseline (never, past and current) and duration of follow-up.

<sup>b</sup>High grade was defined as Gleason 7–10 or poorly differentiated.

<sup>c</sup>Cases with unknown stage or Gleason sum were excluded from the analyses.

<sup>d</sup>Metastatic/fatal prostate cancer, cases died of prostate cancer and those who developed metastasis during the follow-up.

( $\geq$  vs. <median) was associated with a reduced risk of overall prostate cancer (RR, 95% CI = 0.72, 0.55–0.95,  $P_{\text{interaction}} = 0.01$ ; Table IV). The patterns were similar and the RRs were even lower for advanced-stage (RR, 95% CI = 0.45, 0.25–0.82) and for metastatic and fatal disease (RR, 95% CI = 0.47, 0.25–0.88); however, formal tests for interactions were not statistically significant,

which can be due to small number of cases therefore limited power in these subgroup analyses.

## DISCUSSION

In this population of primarily Caucasian U.S. physicians, we found no direct association between

**TABLE III. Prediagnostic Plasma Levels of IGF-I, IGFBP-3 and VEGF by HIF-1 $\alpha$  P582S Genotype<sup>a</sup>**

	HIF-1 $\alpha$ P582S CC		HIF-1 $\alpha$ P582S CT or TT	
	N	Mean (SE)	N	Mean (SE)
IGF-I <sup>a</sup>				
Cases	577	192.6 (2.9)	155	203.1 (4.9)
Controls	557	191.2 (2.9)	130	191.1 (5.4)
IGFBP-3 <sup>b</sup>				
Cases	578	3,145 (33)	155	3,261 (56)
Controls	561	3,187 (33)	130	3,081 (61)
VEGF <sup>c</sup>				
Cases	377	134.3 (34.4)	104	182.0 (58.8)
Controls	338	189.6 (36.5)	88	143.0 (63.8)

<sup>a</sup>Levels by genotype,  $P > 0.05$ .

<sup>b</sup>Age-, smoking status- and batch-adjusted levels.

<sup>c</sup>Age- and smoking status-adjusted levels.

**TABLE IV. Joint Association of the HIF-1 $\alpha$  P582S Polymorphism and Plasma Levels of IGF-I and IGFBP-3 With Prostate Cancer<sup>a</sup>**

HIF-1 $\alpha$ genotype	Plasma level <sup>b</sup>	IGF-I				IGFBP-3			
		No. of ca/co	RR	95% CI	P <sub>interaction</sub>	No. of ca/co	RR	95% CI	P <sub>interaction</sub>
Overall prostate cancer									
CC	Low	266/262	REF			282/251	REF		
	High	248/269	1.00	0.76–1.30		232/280	0.72	0.55–0.95	
CT or TT	Low	66/64	1.02	0.70–1.50	0.76	72/74	0.89	0.61–1.28	0.01
	High	77/62	1.34	0.90–2.00		71/52	1.20	0.78–1.84	
Advanced-stage prostate cancer <sup>c</sup>									
CC	Low	63/72	REF			68/54	REF		
	High	59/54	1.70	0.93–3.09		54/72	0.45	0.25–0.82	
CT or TT	Low	14/16	0.89	0.40–1.96	0.74	18/19	0.66	0.31–1.40	0.14
	High	19/13	2.01	0.87–4.64		15/10	0.92	0.32–2.62	
High-grade prostate cancer <sup>d</sup>									
CC	Low	94/96	REF			92/90	REF		
	High	72/89	0.83	0.52–1.33		74/95	0.81	0.51–1.28	
CT or TT	Low	25/16	1.66	0.82–3.37	0.79	31/21	1.53	0.81–2.90	0.74
	High	28/18	1.72	0.86–3.44		22/13	2.14	0.85–5.36	
Metastatic/fatal prostate cancer <sup>e</sup>									
CC	Low	59/52	REF			61/46	REF		
	High	41/55	0.80	0.43–1.49		39/61	0.47	0.25–0.88	
CT or TT	Low	12/12	0.84	0.36–1.98	0.48	18/15	0.95	0.43–2.10	0.11
	High	16/9	1.68	0.66–4.29		10/6	1.01	0.33–3.11	

<sup>a</sup>Conditional logistic regression, levels of IGF-I and IGFBP-3 were mutually adjusted in all models.

<sup>b</sup>Plasma levels of IGF-I or IGFBP-3, high and low were defined by wave-specific median among controls.

<sup>c</sup>Advanced-stage prostate cancer: stage C or D cancer at diagnosis; cases with unknown stage were excluded from the analyses.

<sup>d</sup>High grade was defined as Gleason 7–10 or poorly differentiated at diagnosis; cases with unknown grade were excluded from the analyses.

<sup>e</sup>Metastatic/fatal prostate cancer, cases died of prostate cancer and those who developed metastasis during the follow-up.

the HIF-1 $\alpha$  P582S or A588T polymorphism and overall or metastatic/fatal prostate cancer. The A588T polymorphism was rare; only 13 cases and 17 controls (<2%) carried the GA variant genotype. The very low frequency of this polymorphism precludes definitive conclusions regarding its effect on prostate cancer incidence, aggressiveness or survivorship.

The lack of significant associations of the HIF-1 $\alpha$  P582S polymorphism with aggressive prostate cancer in our study is somewhat at odds given previous observations. We detected a somatic P582S mutation in an androgen-independent prostate cancer case with metastasis to the bone [13] as did another group in prostate tumor [14]. A case-control study observed higher frequencies of the P582S T- containing variant genotypes among 196 androgen-independent prostate cancer cases compared with 196 controls [15]. Although proline 582 has not been identified as a hydroxylation site necessary to mediate VHL binding [35] and one study on colorectal cancer incidence reported null associations with this polymorphism [36], the P582S variant genotypes (vs. wild-type) yield significantly higher transcription activity under both normoxic and

hypoxic conditions [11–13]. Furthermore, the P582S polymorphism may confer susceptibility to renal cell carcinoma [37,38] and is associated with significantly increased microvessels among patients with head and neck squamous cell carcinoma [11].

We observed a statistically significant interaction between the HIF-1 $\alpha$  P582S polymorphism and baseline plasma IGFBP-3 levels in modifying overall prostate cancer risk (P<sub>interaction</sub> = 0.01, Table IV) [28]. We have previously reported that circulating levels of IGF-I were positively associated (whereas levels of IGFBP-3 were inversely associated) with risk of advanced prostate cancer in the same study population [28]. In the current analysis, the associations of IGFBP-3 with prostate cancer was not observed among men carrying the variant T allele (CT or TT), whereas among those with the CC wild-type, high levels of IGFBP-3 were significantly associated with a 28% reduced risk of overall prostate cancer and over 50% reduced risks of high-stage, metastatic and fatal prostate cancer, although formal tests for interactions were not statistically significant for the subgroups. We recognize that these findings may just be a chance, but they are also

interesting given the fact that IGFBP-3 mRNA is more abundantly expressed in hypoxia-related inflammatory angiogenesis [24,25]; IGFBP-3 is a multifunctional protein that induces apoptosis utilizing both IGF-dependent and IGF-independent mechanisms [26]; and it has direct, IGF-independent inhibitory effects on angiogenesis in vivo [27]. Thus, larger studies are needed to confirm these exploratory findings and the interaction between the *P582S* polymorphism and IGFBP-3 merits further evaluation in mechanistic studies.

VEGF is a pleiotrophic growth factor that promotes endothelial cell proliferation, vascular permeability, and angiogenesis [39,40] and is overexpressed in prostate cancer [41]. Because it is shown that the binding of HIF-1 $\alpha$  to the VEGF promoter is required for maximum transcription of VEGF mRNA following hypoxia [17,18], we had hypothesized that the HIF-1 $\alpha$  *P582S* variant carriers may have higher circulating VEGF levels and therefore higher risk of prostate cancer. The large intra-assay variation of the VEGF measurement, the null association between plasma VEGF level and prostate cancer that we described previously [34] as well as the lack of the interaction with the *P582S* polymorphism in the current study might reflect the difficulty for precise measurements of VEGF in frozen plasma. Improving assays for circulating VEGF levels or its tissue expression would be worthwhile to further evaluate the potential role of VEGF in both carcinogenesis and angiogenesis.

Strengths of the current study include its prospective design, large sample size and complete long-term follow-up. Prospectively collected plasma enabled us to assess the levels of IGF-I, IGFBP3 and their interaction with the HIF-1 $\alpha$  polymorphism. Although a single assessment of biomarker levels from the baseline blood is an imperfect indicator of long-term exposures, a pilot study with blood drawn from the same individuals at a 5-year interval showed a high correlation ( $r=0.75$ ) for IGF-1 (Ma, J, unpublished data). Furthermore, significant associations of plasma levels of IGF-I and IGFBP-3 with prostate cancer risk [28] also provide assurance that these biomarker data are valid in reflecting long-term status in our study population. One limitation of the current study is the limited statistical power for subgroup analyses. In testing for interactions, the low frequency of the *TT* variant genotype allows us to assess the dominant effect only, thus we may not exclude possible chance findings.

To summarize, we found no direct association between either the HIF-1 $\alpha$  *P582S* or *A588T* polymorphism with prostate cancer. However, our data suggest a possible interaction between the *P582S* polymorphism and IGFBP-3 in modifying prostate cancer risk.

## ACKNOWLEDGMENTS

A special thank you goes to all the men in the Physicians' Health Study for their long-term participation and cooperation.

## REFERENCES

1. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci USA* 1993;90(9):4304–4308.
2. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 2003;3(10):721–732.
3. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O<sub>2</sub> tension. *Proc Natl Acad Sci USA* 1995;92(12):5510–5514.
4. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1 $\alpha$  in common human cancers and their metastases. *Cancer Res* 1999;59(22):5830–5835.
5. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1 $\alpha$  and HIF-2 $\alpha$  in normal human tissues, cancers, and tumor-associated macrophages. *Am J Pathol* 2000;157(2):411–421.
6. Zhong H, Agani F, Baccala AA, Laughner E, Rioseco-Camacho N, Isaacs WB, Simons JW, Semenza GL. Increased expression of hypoxia inducible factor-1 $\alpha$  in rat and human prostate cancer. *Cancer Res* 1998;58(23):5280–5284.
7. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL. Modulation of hypoxia-inducible factor 1 $\alpha$  expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. *Cancer Res* 2000;60(6):1541–1545.
8. Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1 $\alpha$  in human normal, benign, and malignant prostate tissue. *Chin Med J* 2003;116(12):1936–1939.
9. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1 $\alpha$  is an early event in prostate carcinogenesis. *Cancer Detect Prev* 2004;28(2):88–93.
10. Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER. The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1 $\alpha$  in renal cell carcinoma. *Oncogene* 2001;20(36):5067–5074.
11. Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, Poellinger L, Nishiyama M. Hypoxia-inducible factor-1 $\alpha$  polymorphisms associated with enhanced transactivation capacity, implying clinical significance. *Carcinogenesis* 2003;24(11):1779–1783.
12. Yamada N, Horikawa Y, Oda N, Iizuka K, Shihara N, Kishi S, Takeda J. Genetic variation in the hypoxia-inducible factor-1 $\alpha$  gene is associated with type 2 diabetes in Japanese. *J Clin Endocrinol Metab* 2005;90(10):5841–5847.
13. Fu XS, Choi E, Bublej GJ, Balk SP. Identification of hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. *Prostate* 2005;63(3):215–221.
14. Anastasiadis AG, Ghafar MA, Salomon L, Vacherot F, Benedit P, Chen MW, Shabsigh A, Burchardt M, Chopin DK, Shabsigh R,

- Buttayan R. Human hormone-refractory prostate cancers can harbor mutations in the O(2)-dependent degradation domain of hypoxia inducible factor-1alpha (HIF-1alpha). *J Cancer Res Clin Oncol* 2002;128(7):358–362.
15. Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg WD. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. *Cancer Biol Ther* 2005;4(11):1222–1225.
  16. Vaupel P. The role of hypoxia-induced factors in tumor progression. *Oncologist* 2004;9 (Suppl 5):10–17.
  17. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 1996;16(9):4604–4613.
  18. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. *Oncogene* 2005;24(19):3110–3120.
  19. Treins C, Giorgetti-Peraldi S, Murdaca J, Monthouel-Kartmann MN, Van Obberghen E. Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. *Mol Endocrinol* 2005;19(5):1304–1317.
  20. Chavez JC, LaManna JC. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: Potential role of insulin-like growth factor-1. *J Neurosci* 2002;22(20):8922–8931.
  21. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. *Cancer Res* 1999;59(16):3915–3918.
  22. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. *J Biol Chem* 2002;277(31):27975–27981.
  23. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. *Nat Rev Drug Discov* 2003;2(10):803–811.
  24. Tucci M, Nygard K, Tanswell BV, Farber HW, Hill DJ, Han VK. Modulation of insulin-like growth factor (IGF) and IGF binding protein biosynthesis by hypoxia in cultured vascular endothelial cells. *J Endocrinol* 1998;157(1):13–24.
  25. Lee WH, Wang GM, Yang XL, Seaman LB, Vannucci SI. Perinatal hypoxia-ischemia decreased neuronal but increased cerebral vascular endothelial IGFBP3 expression. *Endocrine* 1999;11(2):181–188.
  26. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. *Endocrinology* 2006;147(5):2112–2121.
  27. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. *Oncogene* 2006.
  28. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. *J Natl Cancer Inst* 2002;94(14):1099–1106.
  29. Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: A prospective study in a population-based nonscreened cohort. *J Clin Oncol* 2004;22(15):3104–3112.
  30. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. *J Clin Endocrinol Metab* 2000;85(11):4258–4265.
  31. Steering Committee of the Physician's Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *New Engl J Med* 1989;321:129–135.
  32. Gann PH. Prospective study of sex hormone levels and risk of prostate cancer. *J Natl Cancer Inst* 1996;88(16):1118–1126.
  33. Catalona WJ, Aviola LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. *Arch Int Med* 1987;147(2):361–363.
  34. Li H, Kantoff PW, Ma J, Stampfer MJ, George DJ. Prediagnostic plasma vascular endothelial growth factor levels and risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2005;14(6):1557–1561.
  35. Percy MJ, Mooney SM, McMullin MF, Flores A, Lappin TR, Lee FS. A common polymorphism in the oxygen-dependent degradation (ODD) domain of hypoxia inducible factor-1alpha (HIF-1alpha) does not impair Pro-564 hydroxylation. *Mol Cancer* 2003;2:31.
  36. Kuwai T, Kitadai Y, Tanaka S, Kuroda T, Ochiumi T, Matsumura S, Oue N, Yasui W, Kaneyasu M, Tanimoto K, Nishiyama M, Chayama K. Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma. *Oncol Rep* 2004;12(5):1033–1037.
  37. Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. *Cancer Genet Cytogenet* 2004;153(2):122–126.
  38. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. *Oncol Rep* 2005;13(5):859–864.
  39. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 1995;146(5):1029–1039.
  40. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. *Breast Cancer Res Treat* 1995;36(2):127–137.
  41. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. *J Urol* 1997;157(6):2323–2328.